Arg-Gly-OH | 2418-67-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Arg-Gly-OH
• 英文别名: arginyl-glycine；2-[[2-Amino-5-(diaminomethylideneamino)pentanoyl]amino]acetic acid
• CAS: 2418-67-9
• 化学式: C₈H₁₇N₅O₃
• 分子量: 231.255
• InChiKey: XUUXCWCKKCZEAW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.9
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  157
• 氢给体数：
  5
• 氢受体数：
  5

文献信息

• Process for preparing a B30-threonine insulin
  申请人：SHIONOGI & CO., LTD.

  公开号：EP0017938A1

  公开（公告）日：1980-10-29

  A process for preparing a B30-threonine-insulin is described which comprises reacting a des-B30-insulin with an excess amount of a threonine derivative represented by the formulawherein Thr is L-threonine residue, R1 is hydrogen or a hydroxy-protecting group; and R2 is a carboxyl-protecting group, in the presence of an enzyme specifically acting on the basic-amino-acid carbonyl in peptide linkages.

  描述了一种制备 B30-苏氨酸胰岛素的工艺，该工艺包括在一种专门作用于肽键中碱性氨基酸羰基的酶存在的情况下，将去 B30-胰岛素与过量的苏氨酸衍生物进行反应，其中 Thr 为 L-苏氨酸残基，R1 为氢或羟基保护基团，R2 为羧基保护基团。
• Nutrient compositions containing peptides
  申请人：CLINTEC NUTRITION COMPANY

  公开号：EP0457314A1

  公开（公告）日：1991-11-21

  Nutrient compositions comprise an aqueous solution of at least one dipeptide with an N-terminal amino acid selected from glutamine, aspargine, tyrosine, tryptophan, and aspargine. The C-terminal amino acid is alanine, glycine, tryptophan, arginine, proline or serine. The nutritional compositions contain from about 0.1 to 25.0 percent by weight of oligopeptides, preferably about 0.5 to 5.0 percent by weight.

  营养组合物包含至少一种二肽的水溶液，其 N 端氨基酸选自谷氨酰胺、天门冬氨酸、酪氨酸、色氨酸和天门冬氨酸。 C 端氨基酸为丙氨酸、甘氨酸、色氨酸、精氨酸、脯氨酸或丝氨酸。营养组合物含有约 0.1%至 25.0%（按重量计）的低聚肽，最好是约 0.5%至 5.0%（按重量计）。
• NOVEL POLYPEPTIDES AND ANTI-HIV DRUGS CONTAINING THE SAME
  申请人：Seikagaku Corporation

  公开号：EP1323730A1

  公开（公告）日：2003-07-02

  The present invention relates to a polypeptide represented by the formula:         A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit-Cys-A7     (I) (wherein A1 represents a hydrogen atom or an arginine, lysine, ornithine, citrulline, alanine residue, etc.; A2 represents an aromatic amino acid residue; A3, A4 and A6 represent an arginine, lysine, ornithine, citrulline or alanine residue, A5 represents a tyrosine, phenylalanine, alanine, naphthylalanine or citrulline residue; A7 represents a lysine or arginine residue in which a carboxyl group may be amidated; X represents a D-ornithyl-proline, prolyl-D-ornithine, D-lysyl-proline residue, etc.; provided that either of A1, A3, A4, A5, A6 and A7 is an alanine residue, etc., or X is citrulline, etc.) or a salt thereof.

  本发明涉及一种由式表示的多肽： A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit-Cys-A7 (I) (其中 A1 代表一个氢原子或一个精氨酸、赖氨酸、鸟氨酸、瓜氨酸、丙氨酸残基等；A2 代表一个芳香族氨基酸。A2 代表芳香族氨基酸残基；A3、A4 和 A6 代表精氨酸、赖氨酸、鸟氨酸、瓜氨酸或丙氨酸残基，A5 代表酪氨酸、苯丙氨酸、丙氨酸、萘丙氨酸或瓜氨酸残基；A7 代表赖氨酸或精氨酸残基，其中的羧基可能被酰胺化；X 代表 D-鸟氨酰-脯氨酸、脯氨酰-D-鸟氨酸、D-赖氨酰-脯氨酸残基等。条件是 A1、A3、A4、A5、A6 和 A7 中的任一个是丙氨酸残基等、或 X 是瓜氨酸等）或其盐。
• 4F-benzoyl-TN14003 combined with rituximab for use in the treatment of a tumour
  申请人：Biokine Therapeutics LTD.

  公开号：EP2759302A2

  公开（公告）日：2014-07-30

  The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful in cancer therapy.

  本发明涉及 T-140 类似肽的新型治疗用途以及包含 T-140 类似肽的组合物。具体而言，本发明提供了用于癌症治疗的组合物和方法。
• 4F-BENZOYL-TN14003 FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA
  申请人：Biokine Therapeutics LTD.

  公开号：EP2942059A1

  公开（公告）日：2015-11-11

  The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful in cancer therapy.

  本发明涉及 T-140 类似肽的新型治疗用途以及包含 T-140 类似肽的组合物。具体而言，本发明提供了用于癌症治疗的组合物和方法。